CJC-1295 Dosage Guide: Protocols, Timing & How Much to Take (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Dosage Protocols
No FDA-approved dosing guidelines exist for CJC-1295. The following protocols are derived from clinical research and community reports.
CJC-1295 without DAC (Mod GRF 1-29)
Conservative starting dose: 50–100 mcg per injection
Standard dose: 100–200 mcg per injection
Frequency: 1–2 times daily (bedtime dose is considered most important)
Timing: Often administered before bed to coincide with natural GH release, and/or upon waking
Cycle length: 8–12 weeks, followed by 4 weeks off
CJC-1295 with DAC
Starting dose: 300 mcg per injection twice weekly
Maintenance dose: 300–600 mcg once or twice weekly
Cycle length: 8–12 weeks
Cycling Guidelines
Most practitioners recommend cycling CJC-1295 to prevent receptor desensitization and maintain the body's responsiveness to the peptide. A common approach involves 8–12 weeks on, followed by 4–8 weeks off. Some users employ a 5 days on, 2 days off weekly schedule with the non-DAC version to preserve pulsatile release patterns.
Frequently Asked Questions
For CJC-1295 with DAC, simply resume your regular schedule. Do not double dose. For CJC-1295 without DAC, missing occasional doses is less significant due to the frequent dosing schedule; simply continue with your next planned injection.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005.
Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009.
Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011.
Aidsmap. Lipodystrophy study halted after patient death. 2006.
World Anti-Doping Agency. The 2024 Prohibited List International Standard.
FDA. CJC-1295 - Pharmacy Compounding Advisory Committee Materials. December 2024.
Hone Health. Everything You Need to Know About the FDA Peptide Ban.
Innerbody. CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice.